BSECompany Update1d ago · 18 Aug 2026, 06:59 pm

As per PDF attached.

Eiko Lifesciences Ltd · 540204

✦ AI SummaryRegulatory

Eiko Lifesciences Ltd has received communications and recovery proceedings from IDBI Bank regarding an alleged corporate guarantee of ₹58 lakhs issued by the company's erstwhile entity in 1986. The company disputes the claim and is pursuing legal remedies.

Analysis Scores

Earnings Impact2/10
Growth Catalyst1/10
Governance Concern3/10
Regulatory Risk6/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Eiko Lifesciences Ltd - 540204 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015

Attachments (1)

📄

b173e5c8-8147-47a9-b86e-5932d8623573.pdf

pdf

Download →
View document text
Date: 18th August, 2026 Corporate Services Department, BSE Limited, Phiroze Jeejeebhoy Towers, 1st Floor, Dalal Street, Fort, Mumbai - 400001. Scrip Code: 540204 Subject: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015 (“SEBI LODR Regulations”) Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the Stock Exchanges that the Company has received certain communications and recovery proceedings from IDBI Bank Limited ("IDBI Bank") in relation to an alleged corporate guarantee purportedly issued by the Company's erstwhile entity, Narendra Investments (Delhi) Limited, in connection with financial facilities extended to Consolidated Steels & Alloys Limited. As per the document presently provided by IDBI Bank, an alleged corporate guarantee of ₹58 lakhs (Rupees Fifty-Eight Lakhs) was stated to have been issued in 1986. The matter therefore relates to a historical transaction dating back nearly four decades. The Company disputes the alleged claim and has neither admitted nor acknowledged any liability in relation thereto. The Company has already taken appropriate legal steps and is pursuing all available legal remedies in respect of the alleged claim and the consequent recovery proceedings before the appropriate authorities. Based on the facts presently available to the Company and the legal position being pursued, the Management does not expect the matter to have any material financial impact on the Company or its ongoing business operations. The Company shall continue to monitor the matter and make further disclosures, as and when required under applicable laws and regulations. Request you to take the same on record. For Eiko LifeSciences Limited Chintan Doshi Company Secretary & Compliance Officer M. No: A36190 Address: 604, Centrum, Opp TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane West 400 604 Eiko LifeSciences Limited, CIN: L65993MH1977PLC258134 Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604 Mobile No.: +919082668855; Email id: investor.relations@eikolifesciences.com website: www.eikolifesciences.com